These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 34090255)

  • 21. Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: a randomized controlled trial.
    Murrough JW; Burdick KE; Levitch CF; Perez AM; Brallier JW; Chang LC; Foulkes A; Charney DS; Mathew SJ; Iosifescu DV
    Neuropsychopharmacology; 2015 Mar; 40(5):1084-90. PubMed ID: 25374095
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Commentary on Cochrane review: "Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder".
    Borentain S; Desai P; Fu DJ; Nancy Chen L; Lane R; Mathews M; Canuso CM
    J Psychopharmacol; 2023 Aug; 37(8):836-844. PubMed ID: 36218274
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Right dorsolateral prefrontal cortex volumetric reduction is associated with antidepressant effect of low-dose ketamine infusion: A randomized, double-blind, midazolam-controlled PET-MRI clinical trial.
    Li WC; Chen LF; Su TP; Li CT; Lin WC; Wu HJ; Tsai SJ; Bai YM; Tu PC; Chen MH
    J Affect Disord; 2023 Aug; 335():105-110. PubMed ID: 37178823
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A comparative analysis of antidepressant and anti-suicidal effects of repeated ketamine infusions in elderly and younger adults with depression.
    Zheng W; Zhou YL; Wang CY; Lan XF; Ning YP
    J Affect Disord; 2023 Aug; 334():145-151. PubMed ID: 37160235
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effectiveness of repeated intravenous ketamine on depressive symptoms, suicidal ideation and functional disability in adults with major depressive disorder and bipolar disorder: Results from the Canadian Rapid Treatment Center of Excellence.
    McIntyre RS; Rodrigues NB; Lee Y; Lipsitz O; Subramaniapillai M; Gill H; Nasri F; Majeed A; Lui LMW; Senyk O; Phan L; Carvalho IP; Siegel A; Mansur RB; Brietzke E; Kratiuk K; Arekapudi AK; Abrishami A; Chau EH; Szpejda W; Rosenblat JD
    J Affect Disord; 2020 Sep; 274():903-910. PubMed ID: 32664031
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis.
    Wilkinson ST; Ballard ED; Bloch MH; Mathew SJ; Murrough JW; Feder A; Sos P; Wang G; Zarate CA; Sanacora G
    Am J Psychiatry; 2018 Feb; 175(2):150-158. PubMed ID: 28969441
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A preliminary study of anti-suicidal efficacy of repeated ketamine infusions in depression with suicidal ideation.
    Zhan Y; Zhang B; Zhou Y; Zheng W; Liu W; Wang C; Li H; Chen L; Yu L; Walter M; Li M; Li MD; Ning Y
    J Affect Disord; 2019 May; 251():205-212. PubMed ID: 30927581
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Single, Repeated, and Maintenance Ketamine Infusions for Treatment-Resistant Depression: A Randomized Controlled Trial.
    Phillips JL; Norris S; Talbot J; Birmingham M; Hatchard T; Ortiz A; Owoeye O; Batten LA; Blier P
    Am J Psychiatry; 2019 May; 176(5):401-409. PubMed ID: 30922101
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Single, Fixed-Dose Intranasal Ketamine for Alleviation of Acute Suicidal Ideation. An Emergency Department, Trans-Diagnostic Approach: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Trial.
    Domany Y; McCullumsmith CB
    Arch Suicide Res; 2022; 26(3):1250-1265. PubMed ID: 33583341
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neurocognitive performance of repeated versus single intravenous subanesthetic ketamine in treatment resistant depression.
    Shiroma PR; Thuras P; Wels J; Albott CS; Erbes C; Tye S; Lim KO
    J Affect Disord; 2020 Dec; 277():470-477. PubMed ID: 32871534
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antidepressant and anti-suicidal effects of ketamine in treatment-resistant depression associated with psychiatric and personality comorbidities: A double-blind randomized trial.
    Ahmed GK; Elserogy YM; Elfadl GMA; Ghada Abdelsalam K; Ali MA
    J Affect Disord; 2023 Mar; 325():127-134. PubMed ID: 36623562
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of klotho on antidepressant and antisuicidal effects of low-dose ketamine infusion among patients with treatment-resistant depression and suicidal ideation.
    Chen MH; Bai YM; Wu HJ; Li CT; Lin WC; Tsai SJ; Su TP; Tu PC
    J Affect Disord; 2023 Nov; 340():471-475. PubMed ID: 37579883
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Maintenance of antidepressant and antisuicidal effects by D-cycloserine among patients with treatment-resistant depression who responded to low-dose ketamine infusion: a double-blind randomized placebo-control study.
    Chen MH; Cheng CM; Gueorguieva R; Lin WC; Li CT; Hong CJ; Tu PC; Bai YM; Tsai SJ; Krystal JH; Su TP
    Neuropsychopharmacology; 2019 Nov; 44(12):2112-2118. PubMed ID: 31421635
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessing measures of suicidal ideation in clinical trials with a rapid-acting antidepressant.
    Ballard ED; Luckenbaugh DA; Richards EM; Walls TL; Brutsché NE; Ameli R; Niciu MJ; Vande Voort JL; Zarate CA
    J Psychiatr Res; 2015 Sep; 68():68-73. PubMed ID: 26228403
    [TBL] [Abstract][Full Text] [Related]  

  • 35. IN Esketamine and IV Ketamine: Results of a multi-site observational study assessing the effectiveness and tolerability of two novel therapies for treatment-resistant depression.
    Gutierrez G; Swainson J; Ravindran N; Lam RW; Giacobbe P; Karthikeyan G; Kowara A; Do A; Baskaran A; Nestor SM; Kang MJY; Biorac A; Vazquez G
    Psychiatry Res; 2024 Oct; 340():116125. PubMed ID: 39128167
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Participant-Level Integrative Data Analysis of Differential Placebo Response for Suicidal Ideation and Nonsuicidal Depressive Symptoms in Clinical Trials of Intravenous Racemic Ketamine.
    Bloomfield-Clagett B; Ballard ED; Greenstein DK; Wilkinson ST; Grunebaum MF; Murrough JW; Mathew SJ; Phillips JL; Fava M; Sanacora G; Zarate CA
    Int J Neuropsychopharmacol; 2022 Oct; 25(10):827-838. PubMed ID: 35994774
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomized controlled pilot study of daily intravenous ketamine over three days for treatment-resistant depression.
    Pattanaseri K; Lortrakul J; Jaisin K; Srifuengfung M; Sa-Nguanpanich N; Viravan N; Pariwatcharakul P; Makarasara W; Ratta-Apha W
    BMC Psychiatry; 2024 Jul; 24(1):512. PubMed ID: 39026266
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical outcomes in the biomarkers of ketamine (Bio-K) study of open-label IV ketamine for refractory depression.
    Parikh SV; Vande Voort JL; Yocum AK; Achtyes E; Goes FS; Nykamp L; Singh B; Lopez-Vives D; Sera CE; Maixner D; Tarnal V; Severe J; Bartek S; Tye SJ; Rico J; Stoppel CJ; Becerra A; Smart L; Miller CR; Frye MA; Greden JF; Bobo WV
    J Affect Disord; 2024 Mar; 348():143-151. PubMed ID: 38142892
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of intravenous ketamine treatment in anxious versus nonanxious unipolar treatment-resistant depression.
    Salloum NC; Fava M; Freeman MP; Flynn M; Hoeppner B; Hock RS; Cusin C; Iosifescu DV; Trivedi MH; Sanacora G; Mathew SJ; Debattista C; Ionescu DF; Papakostas GI
    Depress Anxiety; 2019 Mar; 36(3):235-243. PubMed ID: 30597688
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A systematic review and meta-analysis of the efficacy of ketamine and esketamine on suicidal ideation in treatment-resistant depression.
    Wang YT; Wang XL; Lei L; Guo ZY; Kan FF; Hu D; Gai C; Zhang Y
    Eur J Clin Pharmacol; 2024 Feb; 80(2):287-296. PubMed ID: 38117332
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.